- Home
- ENTA vs LFVN Comparison
ENTA vs LFVN Comparison
Compare ENTA & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- LFVN
- Stock Information
- Founded
- ENTA 1995
- LFVN N/A
- Country
- ENTA United States
- LFVN United States
- Employees
- ENTA N/A
- LFVN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- LFVN Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- LFVN Health Care
- Exchange
- ENTA Nasdaq
- LFVN Nasdaq
- Market Cap
- ENTA 160.3M
- LFVN 165.9M
- IPO Year
- ENTA 2013
- LFVN N/A
- Fundamental
- Price
- ENTA $7.28
- LFVN $12.53
- Analyst Decision
- ENTA Buy
- LFVN Strong Buy
- Analyst Count
- ENTA 4
- LFVN 2
- Target Price
- ENTA $18.00
- LFVN $30.50
- AVG Volume (30 Days)
- ENTA 168.6K
- LFVN 103.9K
- Earning Date
- ENTA 08-04-2025
- LFVN 05-06-2025
- Dividend Yield
- ENTA N/A
- LFVN 1.44%
- EPS Growth
- ENTA N/A
- LFVN 152.87
- EPS
- ENTA N/A
- LFVN 0.70
- Revenue
- ENTA $64,462,999.00
- LFVN $222,347,000.00
- Revenue This Year
- ENTA N/A
- LFVN $17.36
- Revenue Next Year
- ENTA $0.48
- LFVN $9.60
- P/E Ratio
- ENTA N/A
- LFVN $17.85
- Revenue Growth
- ENTA N/A
- LFVN 8.22
- 52 Week Low
- ENTA $4.09
- LFVN $5.22
- 52 Week High
- ENTA $17.24
- LFVN $27.38
- Technical
- Relative Strength Index (RSI)
- ENTA 60.14
- LFVN 47.18
- Support Level
- ENTA $6.87
- LFVN $12.31
- Resistance Level
- ENTA $8.47
- LFVN $12.90
- Average True Range (ATR)
- ENTA 0.50
- LFVN 0.43
- MACD
- ENTA -0.03
- LFVN 0.02
- Stochastic Oscillator
- ENTA 54.44
- LFVN 33.67
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.